- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01895764
Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) (COMARIS)
September 28, 2015 updated by: University Hospital, Tours
The purpose of this study is to determine if association of methotrexate with adalimumab leads to decrease immunogenicity beside adalimumab alone in Ankylosing Spondylitis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
110
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Blois, France, 41000
- Rhumatologie, CH de BLOIS
-
Brest, France, 29609
- Rhumatologie, CHRU de BREST
-
La Roche Sur Yon, France, 85925
- Rhumatologie, CHD LA ROCHE SUR YON
-
Le Mans, France, 72037
- Rhumatologie, CHR du MANS
-
Nantes, France, 44093
- Rhumatologie, CHRU de NANTES
-
Orleans, France, 45032
- Rhumatologie / IPROS, CHR d'ORLEANS
-
Poitiers, France, 86021
- Rhumatologie, CHRU de POITIERS
-
Rennes, France, 35203
- Rhumatologie, CHRU de RENNES
-
Saint Brieuc, France, 22027
- Rhumatologie, CH de SAINT BRIEUC
-
Saint Nazaire, France, 44606
- Médecine polyvalente, CH de SAINT NAZAIRE
-
Tours, France, 37044
- Rhumatologie, CHRU de TOURS
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subject 18 years of age or older
- Able and willing to give written informed consent and to comply with the requirements of the study protocol
- Subject met the definition of Ankylosing Spondylitis (AS) based on ASAS Criteria
- Subject with active AS, has had an inadequate response, an intolerance or an to one or more nonsteroidal anti-inflammatory drugs
Exclusion Criteria:
- Previous adalimumab treatment or previous treatment with more than one anti TNF alpha therapy.
- Previous methotrexate treatment, not stopped 3 month before inclusion
- Surgery scheduled during study
- Female subject without method of contraception
- Contraindication to adalimumab or methotrexate
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Adalimumab
adalimumab 40mg every 2 weeks
|
adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
Other Names:
|
Experimental: Adalimumab + Methotrexate
adalimumab 40mg every 2 weeks and methotrexate 10mg per week
|
adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
Other Names:
methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
presence or absence of antibodies against adalimumab
Time Frame: 6 months
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline of the Ankylosing Spondylitis Disease Activity Score (ASDAS)
Time Frame: 6 months
|
6 months
|
Change from baseline of T and B cells concentrations.
Time Frame: 6 months
|
6 months
|
Change from baseline of "APRIL" and "TNF alpha" concentrations
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Emilie DUCOURAU, MD, CHRU de Tours
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2013
Primary Completion (Actual)
April 1, 2015
Study Completion (Actual)
April 1, 2015
Study Registration Dates
First Submitted
April 24, 2013
First Submitted That Met QC Criteria
July 5, 2013
First Posted (Estimate)
July 10, 2013
Study Record Updates
Last Update Posted (Estimate)
September 29, 2015
Last Update Submitted That Met QC Criteria
September 28, 2015
Last Verified
September 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Joint Diseases
- Musculoskeletal Diseases
- Arthritis
- Spinal Diseases
- Bone Diseases
- Spondylarthropathies
- Bone Diseases, Infectious
- Ankylosis
- Spondylitis
- Spondylarthritis
- Spondylitis, Ankylosing
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Dermatologic Agents
- Reproductive Control Agents
- Abortifacient Agents, Nonsteroidal
- Abortifacient Agents
- Folic Acid Antagonists
- Adalimumab
- Methotrexate
Other Study ID Numbers
- PHRI12-ED-COMARIS
- 2012-004939-23 (EudraCT Number)
- A130042-32 (Other Identifier: ANSM)
- 2012-R41 (Other Identifier: CPP)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ankylosing Spondylitis
-
Shanghai Junshi Bioscience Co., Ltd.Sponsor GmbHRecruitingActive Ankylosing SpondylitisChina
-
AbbVieBoehringer IngelheimCompletedAnkylosing Spondylitis (AS)
-
Sun Yat-sen UniversityUnknownEarly Ankylosing Spondylitis
-
Tongji HospitalWuhan Central Hospital; Wuhan Hospital of Traditional Chinese MedicineRecruitingAnkylosing Spondylitis (AS)China
-
Chinese University of Hong KongCompletedAnkylosing Spondylitis(AS)China
-
AbbVieCompletedAnkylosing Spondylitis (AS)United States, Australia, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Spain, Sweden, United Kingdom
-
AbbVieCompletedAnkylosing Spondylitis (AS)Taiwan
-
Jiangsu vcare pharmaceutical technology co., LTDRecruitingActive Ankylosing SpondylitisChina
-
Tianjin Hemay Pharmaceutical Co., LtdCompletedActive Ankylosing SpondylitisChina
-
Assiut UniversityUnknownActive Sacroiliitis in Ankylosing Spondylitis
Clinical Trials on Adalimumab
-
PfizerCompletedHealthyUnited States, Belgium
-
PfizerCompletedHealthy SubjectsUnited States
-
AbbottCompletedArthritis, Juvenile IdiopathicUnited States, Belgium, Czech Republic, France, Germany, Italy, Slovakia, Spain
-
Shanghai Henlius BiotechCompleted
-
AbbottCompleted
-
Turgut İlaçları A.Ş.CompletedHealthy ParticipantsGermany
-
Mylan Inc.Mylan GmbHCompletedPsoriasis | Arthritis, PsoriaticBulgaria, Estonia, Hungary, Poland, Russian Federation, Ukraine
-
AbbottCompletedRheumatoid ArthritisSpain
-
SandozHexal AGCompletedPlaque Type PsoriasisUnited States, France, Bulgaria, Slovakia